PETS
PetMed ExpressADocument history
Earnings documents stored for PETS.
Investor releaseQuarter not tagged2026-05-29PetMed Express, Inc. to Report Fourth Quarter and Fiscal Year 2026 Financial Results on Tuesday, June 2, 2026
GlobeNewswire
PetMed Express, Inc. to Report Fourth Quarter and Fiscal Year 2026 Financial Results on Tuesday, June 2, 2026
DELRAY BEACH, Fla., May 29, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) today announced it will report financial results for the fourth quarter and fiscal year ended March 31, 2026, on Tuesday, June 2, 2026 after market close. The Company will host a conference call and webcast to discuss these results at 4:30pm Eastern Time on the same day. Date: Tuesday, June 2, 2026Time: 4:30pm Eastern Time (1:30pm Pacific Time)U.S. dial-in number: 877-407-0789International number: 201-689-8562Webcast: 4Q Earnings Webcast A telephonic replay of the conference call will also be available after 7:30 PM Eastern Time on the same day through June 16, 2026. Toll-free replay number: 844-512-2921 International replay number: 412-317-6671 Replay passcode: 13760873 About PetMed Express, Inc. Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness, pets and pet parents, and the veterinarians who serve them. Through its PETS family of brands and through its PetCareRx subsidiary, the Company offers a comprehensive range of pet health solutions - including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com. Investor Contact:ICR, LLCReed Anderson(646) [email protected]
Investor releaseQuarter not tagged2025-12-20PetMed: Fiscal Q1 Earnings Snapshot
Associated Press Finance
PetMed: Fiscal Q1 Earnings Snapshot
DELRAY BEACH, Fla. (AP) — DELRAY BEACH, Fla. (AP) — PetMed Express Inc. (PETS) on Friday reported a loss of $34.2 million in its fiscal first quarter. The Delray Beach, Florida-based company said it had a loss of $1.65 per share. Losses, adjusted for asset impairment costs, were 34 cents per share. The pet pharmacy company posted revenue of $51.2 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PETS at https://www.zacks.com/ap/PETS
Investor releaseQuarter not tagged2025-12-20PetMed: Fiscal Q2 Earnings Snapshot
Associated Press Finance
PetMed: Fiscal Q2 Earnings Snapshot
DELRAY BEACH, Fla. (AP) — DELRAY BEACH, Fla. (AP) — PetMed Express Inc. (PETS) on Friday reported a loss of $8.5 million in its fiscal second quarter. On a per-share basis, the Delray Beach, Florida-based company said it had a loss of 41 cents. The pet pharmacy company posted revenue of $44.4 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PETS at https://www.zacks.com/ap/PETS
Investor releaseQuarter not tagged2025-11-13PetMed Express, Inc. Announces Preliminary Second Quarter Results and Filing of Form 12b-25; Company Receives Expected Notice of Non-Compliance from Nasdaq
GlobeNewswire
PetMed Express, Inc. Announces Preliminary Second Quarter Results and Filing of Form 12b-25; Company Receives Expected Notice of Non-Compliance from Nasdaq
DELRAY BEACH, Fla., Nov. 13, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. d/b/a PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the “Company”), today announced preliminary second quarter fiscal year 2026 results and filed a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission. The Company is unable to file its Form 10-Q for the quarter ended September 30, 2025 within the prescribed time period without unreasonable effort or expense. Preliminary Second Quarter Net Sales: For the fiscal second quarter ended September 30, 2025, net sales are estimated to range from $43.4 million to $44.5 million compared to $58.0 million (as restated) in the prior year period. For the six months ended September 30, 2025, net sales are estimated to range from $94.5 million to $95.6 million compared to $124.3 million (as restated) in the prior year period. The Company is unable at this time to provide a reasonable estimate of operating income or net income for the three- and six-month periods ended September 30, 2025, due to an ongoing analysis of the timing and amount of an anticipated goodwill impairment charge that was previously discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2025, that was filed on October 14, 2025 (see Note 19 to the Consolidated Financial Statements included in said Form 10-K). The Company had $36.1 million of cash and no debt as of September 30, 2025. The financial information provided herein is estimated and unaudited, and the Company’s actual results may differ from these results due to final adjustments and developments that may arise or information that may become available between now and the time the Company’s financial statements are finalized and included in the Company’s Form 10-Q for the quarter ended September 30, 2025. Receipt of Notice of Non-Compliance from Nasdaq: On November 12, 2025, the Company received an expected notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), which indicated that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 (the “Q2 10-Q”), in addition to its continued delinquency in filing its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 (the “Q1 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)...
Investor releaseQuarter not tagged2025-10-15PetMeds® Files Form 10-K for Fiscal 2025
GlobeNewswire
PetMeds® Files Form 10-K for Fiscal 2025
DELRAY BEACH, Fla., Oct. 14, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (the “Company”) dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today filed with the Securities and Exchange Commission (SEC) its Annual Report on Form 10-K for the fiscal year ended March 31, 2025. Fiscal 2025 Financial Highlights Net sales of $227.0 million for fiscal 2025, below the preliminary estimated range of $231.6 million to $233.6 million, primarily due to the previously announced restatement of promotional sales reimbursements from revenues to cost of sales, which had no impact on net income Net loss of $6.3 million, more than the previously announced preliminary estimated range of $4.5 million to $5.0 million, primarily due to the previously announced $1.2 million non-cash impairment charge for intangible assets Cash of $54.7 million as of March 31, 2025, and no debt “We greatly appreciate the patience of our shareholders over the past several months,” said Board Chair and Interim CEO Leslie C. G. Campbell. “With our Form 10-K for fiscal 2025 now filed and actions taken to enhance our internal processes, we can now fully dedicate our efforts to operational execution and building a platform for long-term value creation. Most importantly we will continue to deliver to our customers the care they trust, which has been our legacy as a pioneer in the digital pharmacy industry for nearly 30 years. We now plan to file, as soon as practicable, our Quarterly Report on Form 10-Q for the first quarter ended June 30, 2025, followed by our earnings results and corresponding filings for the second quarter ended September 30, 2025, and thereby resume the normal quarterly reporting schedule. While we are unable at this time to determine exact dates for our Q1 and Q2 filings with the SEC or the related earnings announcements, we expect to resume our normal cadence of quarterly earnings calls promptly once our SEC filings are current.” About PetMed Express, Inc. Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness and the veterinarians who serve them. Through its PETS family of brands, the Company offers a comprehensive range of pet health solutions - including top-brand and generic pharmaceutica...
Investor releaseQuarter not tagged2025-07-01PetMed Express, Inc. Provides Update on Status of Fourth Quarter and FY 2025 Results and Form 10-K Filing
GlobeNewswire
PetMed Express, Inc. Provides Update on Status of Fourth Quarter and FY 2025 Results and Form 10-K Filing
DELRAY BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (the “Company”) dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today provided an update on the status of its fourth quarter and FY 2025 results and 10-K filing. On June 16, 2025, the Company filed a Form 12b-25 (the “Form 12b-25”) disclosing that the Company would be unable to file its Form 10-K for the year ended March 31, 2025 (the “2025 Form 10-K”) within the prescribed period without unreasonable effort or expense. The extension period provided under Rule 12b-25 expires on July 1, 2025. The Company will be unable to file its 2025 Form 10-K within the extension period because the Company is continuing to compile, review, and analyze the information necessary to complete its financial statements and related disclosures to be included in the 2025 Form 10-K. Specifically, the Audit Committee of the Company’s Board of Directors has advised management that it has received anonymous reporting through the Company’s third-party-administered whistleblower hotline regarding: the timing of revenue recognition with respect to certain autoship orders in the fiscal fourth quarter of 2025, some of which resulted in customer complaints; a fiscal fourth quarter 2025 $50 coupon promotion to customers and its potential impact on Company key-performance indicators (KPIs) regarding new customers; and the Company’s culture and control environment. The Audit Committee has engaged external legal counsel with other external advisors to investigate these reports. The investigation is still ongoing, no conclusions have been reached, and the Company cannot predict its duration or outcome. However, based on evidence gathered to date, the Company does not currently expect that this investigation will have a material impact on its previously announced preliminary financial results for the fourth quarter and fiscal year ended March 31, 2025 or the Company’s previously filed financial results. The Company is working diligently to complete its review and file the 2025 Form 10-K as soon as practicable. About PetMed Express, Inc. Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness and the veterinarians who serve them. Th...
Investor releaseQuarter not tagged2025-06-16PetMed Express, Inc. Announces Preliminary Fourth Quarter and FY 2025 Results and Filing of Form 12b-25
GlobeNewswire
PetMed Express, Inc. Announces Preliminary Fourth Quarter and FY 2025 Results and Filing of Form 12b-25
DELRAY BEACH, Fla., June 16, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced preliminary fourth quarter and fiscal year 2025 results and filed Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission. The Company is unable to file its Annual Report on Form 10-K for the fiscal year ended March 31, 2025 within the prescribed time period without unreasonable effort or expense. The Company expects to file its Annual Report on Form 10-K with the Securities and Exchange Commission as soon as practicable, and no later than July 1, 2025, in accordance with Rule 12b-25. Preliminary Fourth Quarter and FY 2025 Results: For the fiscal fourth quarter ended March 31, 2025, net sales are estimated to range from $51.1 million to $53.1 million compared to $66.5 million in the prior year period. Net loss is estimated to range from $9.9 million to $10.4 million compared to a net loss of $5.0 million in the prior year period. Net loss includes the tax expense impact of recording a valuation allowance on the Company’s net deferred tax assets of $6.4 million. For the fiscal year ended March 31, 2025, net sales are estimated to range from $231.6 million to $233.6 million compared to $281.1 million in the prior year. Net loss is estimated to range from $4.5 million to $5.0 million compared to a net loss of $7.5 million in the prior year. Included in the net loss is (1) the benefit of $8.7 million recorded in the fiscal first quarter from the one-time non-cash stock compensation reversal associated with an executive departure and (2) the tax expense impact of recording a valuation allowance on the Company’s net deferred tax assets of $6.4 million recorded in the fiscal fourth quarter. The Company had $54.7 million of cash and no debt as of March 31, 2025. The estimated financial information provided herein is estimated and unaudited and the Company’s actual results may differ from these results due to final adjustments and developments that may arise or information that may become available between now and the time the Company’s financial statements are finalized and included in the Company’s Form 10-K for the fiscal year ended March 31, 2025. The Company will reschedule its fourth quarter and fiscal year 2025 earnings release and conference call and announce the timing once the fil...
Investor releaseQuarter not tagged2025-06-11PetMed Express, Inc. Announces Delay in Fourth Quarter and Fiscal Year End Earnings Release and Conference Call
GlobeNewswire
PetMed Express, Inc. Announces Delay in Fourth Quarter and Fiscal Year End Earnings Release and Conference Call
DELRAY BEACH, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced it is delaying the release of the Company’s fourth quarter and fiscal year 2025 earnings release and subsequent conference call, which had been scheduled for June 10, 2025, because the Company requires additional time to complete the year-end audit process. The Company anticipates that it will issue the earnings release, hold the related conference call, and file its Annual Report on Form 10-K as soon as possible, but no later than June 16, 2025. About PetMed Express, Inc. Founded in 1996, PetMeds is a leader in pioneering the digital pet pharmacy industry. As a national online retailer, PetMeds.com and PetCareRx.com are top choices for delivering preventive and chronic symptom prescriptions and OTC medications and products through their thousands of veterinary partners and a loyal customer base. Leveraging telehealth and insurance partnerships, they offer value and convenience to pet families at every stage of their pets' lives, whether dogs, cats, or horses. PetMeds and PetCareRx provide a comprehensive range of medications, food products, and essential supplies through their websites, www.PetMeds.com and www.PetCareRx.com. Investor Contact: ICR, LLC John Mills (646) 277-1254 Reed Anderson (646) 277-1260 [email protected]
Investor releaseQuarter not tagged2025-06-11PetMed Express Delays Fiscal Q4 Results
MT Newswires
PetMed Express Delays Fiscal Q4 Results
PetMed Express (PETS) said Tuesday it has delayed the release of its Q4 and fiscal 2025 results as i
Investor releaseQuarter not tagged2025-06-09Earnings To Watch: PetMed Express Inc (PETS) Reports Q4 2025 Result
GuruFocus.com
Earnings To Watch: PetMed Express Inc (PETS) Reports Q4 2025 Result
PetMed Express Inc (NASDAQ:PETS) is set to release its Q4 2025 earnings on Jun 10, 2025. The consensus estimate for Q4 2025 revenue is $54.00 million, and the earnings are expected to come in at -$0.05 per share. The full year 2025's revenue is expected to be $231.60 million and the earnings are expected to be $0.23 per share. More detailed estimate data can be found on the Forecast page. Warning! GuruFocus has detected 3 Warning Signs with PETS. Revenue estimates for PetMed Express Inc (NASDAQ:PETS) have remained steady at $231.60 million for the full year 2025 and at $227.00 million for 2026 over the past 90 days. Earnings estimates have also remained unchanged at $0.23 per share for the full year 2025 and at -$0.07 per share for 2026 over the past 90 days. In the previous quarter of 2024-12-31, PetMed Express Inc's (NASDAQ:PETS) actual revenue was $52.98 million, which missed analysts' revenue expectations of $59.60 million by -11.10%. PetMed Express Inc's (NASDAQ:PETS) actual earnings were -$0.03 per share, which missed analysts' earnings expectations of $0.01 per share by -400.00%. After releasing the results, PetMed Express Inc (NASDAQ:PETS) was down by -14.04% in one day. Based on the one-year price targets offered by 2 analysts, the average target price for PetMed Express Inc (NASDAQ:PETS) is $3.60 with a high estimate of $4.00 and a low estimate of $3.20. The average target implies a downside of -9.09% from the current price of $3.96. Based on GuruFocus estimates, the estimated GF Value for PetMed Express Inc (NASDAQ:PETS) in one year is $9.96, suggesting an upside of 151.52% from the current price of $3.96. Based on the consensus recommendation from 2 brokerage firms, PetMed Express Inc's (NASDAQ:PETS) average brokerage recommendation is currently 3.5, indicating a "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell. This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data...
Investor releaseQuarter not tagged2025-05-28PetMed Express, Inc. Sets Fourth Quarter and Full Fiscal Year 2025 Earnings Call
GlobeNewswire
PetMed Express, Inc. Sets Fourth Quarter and Full Fiscal Year 2025 Earnings Call
DELRAY BEACH, Fla., May 27, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) will hold a conference call on Tuesday, June 10, 2025 at 4:30pm Eastern Time to discuss its financial results for the fourth quarter and full fiscal year ended March 31, 2025. Financial results will be issued in a press release prior to the call. PETS management will host the conference call, followed by a question-and-answer period. Please call the conference telephone number 5-10 minutes prior to the start time. Date: Tuesday, June 10, 2025 Time: 4:30pm Eastern Time (1:30pm Pacific Time) U.S. dial-in number: 877-407-0789 International number: 201-689-8562 Webcast: 4Q Earnings Webcast A telephonic replay of the conference call will also be available after 7:30 PM Eastern Time on the same day through June 24, 2025. Toll-free replay number: 844-512-2921 International replay number: 412-317-6671 Replay passcode: 13753433 About PetMed Express, Inc. Founded in 1996, PetMeds is a pioneer in the direct-to- consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness and the veterinarians who serve them. Through its PETS family of brands, the company offers a comprehensive range of pet health solutions - including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com. Investor Contact: ICR, LLC John Mills (646) 277-1254 Reed Anderson (646) 277-1260 [email protected]
TranscriptFY2025 Q32025-02-10FY2025 Q3 earnings call transcript
Earnings source - 24 paragraphs
FY2025 Q3 earnings call transcript
Greetings and welcome to PetMed Express Third Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Reed Anderson with ICR. You may begin.
Thank you, and welcome to the PetMed Express fiscal third quarter 2025 earnings conference call. Certain information included during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Securities Exchange Act of 1934 as amended that may involve a number of risks and uncertainties. These statements are based on our beliefs as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties and assumptions. Actual results could differ materially from those projected. There can be no assurance that any forward-looking results will occur or be realized and nothing contained in this presentation is or should be relied upon as a representation or warranty as to any future matters, including any matter in respect of the operations or business or financial condition of PetMed's. PetMed's undertakes no obligation to update publicly these forward-looking statements based on subsequent events, except as may be required by applicable law, regulation or other competent legal authority. We've identified various risk factors associated with our operations in our most recent annual report and other filings with the Securities and Exchange Commission. Now, let me turn the call over to our CEO and President, Sandra Campos. Sandra?
Thank you, Reed, and welcome to everyone joining our call this afternoon. Following my remarks, Robyn will provide a detailed overview of our financial results, after which we'll open the lines for your questions. Over the past nine months, I have emphasized that our focus remains steadfast on the strategic initiatives pivotal to repositioning PetMed and PetCareRx for long-term success. I have clearly outlined our vision to position PETS as a leader in consumer pet healthcare. While we're still in the early stages of this transformation and have much more work ahead, I am pleased to report that we have made significant progress in validating our strategic direction. We're confident that the actions we're taking will drive differentiation and sustainable growth. Our highest priority has been to return the company to profitability. We achieved this by implementing cost cutting measures and consolidation strategies to integrate PetCareRx operations into the PetMeds organization, targeting $5 million in annualized savings, and we remain on track to meet this milestone. For this quarter Q3, we achieved $2 million in adjusted EBITDA representing a $1.1 million improvement year-over-year while lowering G&A expenses by $2.6 million, compared to last year. As we continue to execute our turnaround strategy, we remain committed to driving shareholder value through growing our customer base, operational discipline and financial efficiency. At PETS, we serve three core communities. First, our pet parents. We're continuously enhancing the digital shopping experience to provide convenient access to pet health solutions. Second, our veterinarian partners. Our investments in Rx approval efficiency through an optimized vet portal, are driving increased adoption and streamline workflows. And third, the pets, dogs, cats and horses that we love and care for. Innovation is at the heart of our approach, ensuring that we offer proven premium health solutions across all categories and life stages. Expanding our customer base and increasing market share remains a top priority. To grow and acquire customers as a digital retailer, we require a modernized tech stack and a seamless shopping experience that meets evolving customer expectations. We have made meaningful progress in this area including website and mobile enhancements, where we executed a full website refresh in November and also relaunched our iOS and Android mobile apps. We implemented Buy Now, Pay Later as a new payment option at checkout, expanding on affordable and accessible choices for our consumers, and in collaboration with our Veterinary Advisory Board, we continue to enhance our veterinary portal, and also launched pethealthmd.com an educational platform offering expert backed pet health guidance. These improvements led to 84,000 gross new customers or 63,000 new customers that had orders shipped during the quarter. Our gross order average order value or AOV increased by 7% at $108 versus $101 last year, while our shipped order AOV rose by 4.3% of $97 versus $93 year-over-year. We are committed to pet health and wellness, through product differentiation and best-in-class customer service. Our SKU optimization strategy ensures that we offer comprehensive health solutions across all life stages, while maintaining strong margins and growth thresholds. To enhance efficiency, we eliminated 4,000 underperforming SKUs, making room for high value products that align with our strategy and also resonate with consumers. Notably, our inventory efficiency has improved, with inventory turn rising to 1.5 in Q3, compared to 1.1 in Q2 and 0.9 last year. This improvement comes alongside a 66% reduction in total inventory on hand, totaling $11.8 million at the end of our third quarter versus $34.6 million last year. During Q3, we advanced our customer call center operations, by integrating an AI driven workforce management tool, to flex and scale our agent population and adapt to changing volumes. This helped us improve our key metrics such as increased sales per agent of 18.8%, and a 3.4% increase in AOV average order value for orders driven by the call center. During our last earnings call, I highlighted our focus on retention, and the operational upgrades that laid the foundation for future growth. While we intended to ramp up performance marketing efforts in in this quarter, we encountered a highly competitive and promotional holiday environment, particularly between Black Friday and year end. With real time insights, we made the strategic decision to prioritize margin protection over aggressive promotions, ending the quarter with $2.8 million less in gross advertising spend year-over-year. As a result, our sales and new customer acquisition during that period, fell short of initial expectations. However, this intentional pivot was necessary in order to maintain financial discipline. Recognizing the need for a marketing strategic reset, we are refining our approach to ensure sustainable, profitable growth. Our top of funnel initiatives such as radio and connected TV, continue to promote our Care You Trust message, and establish brand authority and brand awareness. This is a long-term investment that we've recently begun and includes things like sports team partnerships, podcasts, billboards and local pet adoption events, all of which we've done in this quarter. We are refining acquisition strategies, by rolling out a new email design system and creating stronger segmentation, personalization and dynamic content across our paid platforms. Early indicators show promise, with revenue per email increasing 9% in the month of January, engagement rates have increased quarter-over-quarter that would be inclusive of open rate, click through rate, revenue per email through stronger content and more relevant branding. We believe this is a strong indicator of future conversion improvements. Beyond customer facing upgrades, we have strengthened our core systems with strategic technology investments, to ensure a resilient and secure digital ecosystem for customer data and privacy. Over the past seven months, we resolved OMS issues that previously impacted performance, and continue to modernize our tech stack. In mid-November, we successfully replatformed our autoship recurring subscription program, without disruption and have seen improvements in autoship signups and credit card rejection rates. Although still in early age, tracking our new website performance shows PDP views increased by 30%, bounce rates declined by 6.5 basis points and channel visits increased 7.6% year-over-year. This growth in visits was offset by lower conversion, and we are actively addressing those conversion rate challenges, through search functionality improvements, PDP enhancements and visible promotions. Looking ahead while the competitive landscape remains dynamic, we are executing a disciplined transformation that prioritizes the customer experience, from order placement to last mile delivery, while simultaneously enhancing the infrastructure necessary to support this. We believe these efforts will drive sustained growth, customer loyalty and increased shareholder value. In the short-term, we anticipate increased investments to enhance the customer engagement, customer acquisition and the underlying infrastructure needed. We will continue to strengthen vendor partnerships and expand our portfolio with science backed, veterinary recommended products across our pharmacy, Rx products, OTC over the counter and our food categories. We remain focused on capturing our share of the companion animal health market, by refining our customer experience, optimizing our product mix and strengthening the customer acquisition strategies. As we build a stronger, more efficient organization, we stay true to our core purpose, ensuring pets have homes and live healthier, happier lives. This commitment extends beyond our business, as we actively support shelters, facilitate adoption events and provide aid to pet communities impacted by the LA wildfires, reinforcing our dedication to pet welfare, and the people who care for them. With that, I'll turn the call over to Robyn for a more detailed review of our financial results.
Thank you, Sandra. I will now provide an update on third quarter fiscal year 2025 results, for the period ending December 31, 2024. Net sales were $53 million, compared to $65.3 million in the same period last year, a 19% decline primarily driven by a 34% reduction in gross advertising. As we rebalanced for profitability. We welcomed approximately 63,000 new customers who received an order from us this quarter. Gross profit was $14.9 million versus $17.9 million last year. As a percent of sales, gross profit this year was 28.1%, an 80 basis point improvement, compared to the prior year quarter due to a favorable sales mix, and lower discount activity similar to what we saw in Q2. General and administrative expenses, for the third quarter were $10.8 million versus $13.4 million last year, a 19.7% decrease. This year-over-year improvement was driven by a decrease in stock-based compensation expense, a decrease in payroll and payroll related expense, and to a lesser extent a decrease in credit card processing fees driven by lower sales. Our advertising expenses for the third quarter were $3 million, compared to $5.8 million last year. This decrease can be mainly attributed to lower gross media spend and a higher proportion of that spend being funded by third-party partners. As Sandra mentioned, we purposely pulled back our marketing efforts, to reset our marketing foundation and improve profitability for the quarter. Net loss for the third quarter was $700,000 or $0.03 per diluted share, a meaningful improvement, compared to the net loss of $2 million or $0.10 per diluted share for the same period last year. Adjusted EBITDA of $2 million, compared to $900,000 in the prior year period. Our balance sheet remains strong and as of December 31, 2024, we had $50 million of cash and cash equivalents and no debt. We would now like to open the call for questions, and then after that Sandra will provide some concluding remarks. Operator?
Thank you. [Operator Instructions] And our first question comes from the line of Erin Wright with Morgan Stanley. Please proceed with your question.
Great, thanks. I wanted a quick housekeeping one before I get into it. On the new customer or customer count numbers, I guess do you have. I just want to make sure we're comparing apples-to-apples, kind of on a year-over-year basis. But do you have growth rates around those and how you're kind of defining the different categories from a customer standpoint?
From a customer perspective, on the new customer, what we shared is that we had 63,000 new customers in this quarter with shipped orders. Correct?
Okay. Okay. Just wanted to clarify that. And then on the SKU count rationalization. So does that meaningfully impact your overall kind of revenue growth, or have you quantified that? I mean, I assume it's underperforming SKUs, but how do we think about that? And then also the flow through from a mix perspective?
Yes, it actually did not really impact the revenues. A lot of those SKUs happen to be SKUs that were drop shipped from drop-ship vendors as well. And so, they were not impactful. It was very minimal in terms of any impact over the year. But for the most part when we looked at the SKU optimization, it was about tracking to products that actually had consistent sales over three, four, five and six months, time period. So anything beyond that that had not seen consistent sales, is where we were reducing. So it was definitely not impacting our sales.
Okay. Great. And then just thinking about sort of the underlying backdrop in the market. Like how do you, how would you characterize kind of the trends you are seeing from a customer perspective, and how they're responding maybe to price increases across kind of pet prescriptions that we've been seeing, and hearing about even year-to-date, and how you're thinking about kind of the outlook of the market, just generally speaking. And then if I could sneak one last one in there. Just on the cost savings, obviously you've executed on that. And what's left in terms of the lingering cost savings from the PetCareRx transaction? Thanks.
Let's start with the second one first. So as we look at our cost optimization, and the strategies that we've employed on folding PetCareRx into the organization, we still have more that we are deliberately working on now. And that not only just includes the first phase that we did and executed, which had to do with people, technology, some technology, as well as some outsourced agencies that we're reduplicating. But in addition to that, now as we go into Phase 2 and the second part of it, it actually is more of the technology reduction consolidation that actually, will continue to show an improved balance in terms of what our expenditures are. Do you want to add anything to Robyn?
No, that's right, that's right. And it's a strategy that'll take us over a couple of quarters to execute.
Sorry. Okay. So that was question number two. Going back to question number one, it is without a doubt that the customer continues to be pressured. And as we know, we're seeing a bit more of stabilization as it relates to adoption and pets in general. But we're still seeing that there are reduced visits to the veterinarian, there's some reduced prescriptions. We have not seen our UPTs and Rx and pharmacy actually change from a year ago. So it's still, they're still buying the same amount of times and frequency per year. So it's still about 2.7 times a year that the average prescription, they're coming back to get a prescription again. And that fluctuates based on seasonality, especially as we talk about a flea and tick season per se. But yes, they are absolutely pressured in terms of where they're spending, how they're spending. And we are seeing a bit more as it relates to opening price points, take over some of the more premium price points. That said, we still have a higher household income consumer who spends, who has a household income over $100,000 and that $100,000 to $150,000 and $150,000 plus household income is continuing to spend. And does not have and is not exhibiting some of the same behavior that other customers are with regards to, not being in compliance on the prescription and less spend on their products that relates specifically to pharmacy.
Okay. Thank you.
Thank you. Our next question comes from the line of Ryan Meyers with Lake Street Capital Markets. Please proceed with your question.
Hi guys, thanks for taking my questions. And Sandra, this is kind of a follow-up from the last question that you had as far as just, you know, what you're seeing across your core consumer, and them kind of being a higher household income. But that said, I mean, we've now seen three consecutive quarters of over double-digit revenue declines. I know you guys are pulling back a little bit on the marketing spend, which obviously is impacting the revenue growth. But can you kind of talk about, what else you're seeing here as far as what's driving the softness?
Well, our softness as it relates to where we've been, and you've heard me talk about this a bit as well. One of the reasons that we actually modernized our website, is because we have not captured a younger, more millennial or Gen Z consumer. So as we think about not only what's happening from a consumer behavior standpoint, people are taking longer to have children. And/or their pets are becoming their children, and they're spending more on their children - on those pets are their children essentially in the millennial and Gen Z demographic. So we are modernizing, we are fine tuning our messaging, our content, all of the different platforms in, which we are competing so that we can actually capture that customer. That's not where we've been as a business over many years. So for us, we're actually transitioning that. And as we transition away from a core customer that may have been a little bit older, that new to 1-800-PetMeds brand, because of all of those many years, obviously 28 years, worth of great heritage the company has had. We're trying to also make sure that we're capturing the millennial and Gen Z consumer who is spending, who is focused on more digital experience experiences, who's buying online, is accustomed to it. And that's what you're seeing now, as we've repositioned our marketing and the efforts on marketing that goes into content, it goes into the different channels in which we show up. And we know and understand that this is going to take and require multiple touch points that, the consumer is going to see our brand, before they actually start to engage and then convert.
Got it. And then, as we think about the rest of this year and into next year, when you guys are well capitalized with $50 million of cash on the balance sheet. I mean, how are you evaluating potentially investing more heavily into marketing, kind of running more promotions, really to try to drive revenue growth back into the business, or even just new customer growth back into the business. Any commentary there would be helpful?
Yes, we definitely think about, capital allocation and of course, how to drive our transformation faster. As Sandra mentioned, right on the marketing front, we are resetting, I would say, that the marketing foundation. So we want to do it in a way that's smart, that's going to be the most beneficial in terms of the ROI. We have to kind of set the foundation and get ready to go. Additionally, we're investing in our customer experience. It's critically important that we have the right product assortment, we can get to the customer faster and that the customers have ease of use on our site. And so, we're going to continue to make those foundational investments. And then we can really, I would say, open the floodgates to some extent, right. And start spending more heavily in the marketing area.
And Ryan, I would just add to what Robyn said, just to double click on this point. In order for us to be competitive in today's environment, and the consumer expectations is that you're going to get product same day, next day, or within two days. And so, she was just mentioning last mile delivery as another key target, key focus area for us. We are focused on that customer experience, which has so many different legs to this. And we need to make sure that we are delivering on a timely basis as well. So those investments are coming. We're actually investing in that in this quarter of Q4, as well as starting to increase more on marketing as we go forward.
Great. Thanks for taking my questions.
Thank you. And this does concludes, we have reached the end of the question-and-answer session. I'll now turn the call back over to CEO, Sandra Campos for closing remarks.
Thank you, and thanks for the questions, for the time and the support of PetMed. We understand that this is a transformation on many levels and it is steady. And the key initiatives that we discussed today, are about prioritizing profitability and the customer growth. Lastly, I just want to thank all of our employees, for their constant commitment and the dedication to our customers, the pets that we serve, and to our shareholders. So we look forward to continuing to update you, on our progress during our next conference call. Thank you.
Thank you. This does conclude today's conference, and you may disconnect your lines at this time. Thank you for your participation.

